Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 199.20

+0.1%

Nov 21 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Machaon who wrote (19102)	4/17/1998 9:35:00 AM
From: Henry Niman	Read Replies (1) of 32384

CNBC just indicated that LLY was expect to open higher because of positive comments by Morgan Stanley on Evista's potential as breast cancer prevention. A strong report is expected next month at ASCO. Yesterday, Paine Weber was not as optimistic about Evista: EVISTA (osteoporosis)--LLY's new osteoporosis drug is off to a disappointing start with 53,000 total prescriptions in March. More importantly, the weekly trends are showing positive, but slow sequential growth (consistently less than 1,000 additional new prescriptions per week). While we do expect the trends to improve in the second half of the year (as additional breast cancer and fracture data become available), we did recently lower our 1998 U.S. revenue estimate is $125 million.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next